|Bid||23,310.00 x 0|
|Ask||23,990.00 x 0|
|Day's Range||22,424.00 - 23,716.00|
|52 Week Range||10,298.00 - 23,716.00|
|Beta (5Y Monthly)||0.72|
|PE Ratio (TTM)||2,243.73|
|Earnings Date||Sep 01, 2021|
|Forward Dividend & Yield||2.62 (1.11%)|
|Ex-Dividend Date||Sep 21, 2021|
|1y Target Est||N/A|
Aspen Pharmacare said on Thursday it was in talks to make Johnson & Johnson's coronavirus shot under licence in South Africa, at what would be the continent's first major independent distribution base for a global vaccine against COVID-19. News of the talks coincided with the suspension of heavily criticised shipments to Europe from Africa of the same shot, which is already being made under contract and packaged by Aspen but distributed by J&J.
South Africa's Aspen Pharmacare wants to model itself on India's Serum Institute by getting a licence to manufacture Johnson & Johnson's (J&J) COVID-19 vaccine, Aspen Chief Executive Stephen Saad said on Thursday.
South Africa's Aspen Pharmacare is in talks with Johnson & Johnson over a licence to manufacture, market and sell COVID-19 vaccines in South Africa, according to a company presentation uploaded on its website on Thursday morning. "If successful with a licence, Aspen will not only have manufacturing but will also have the rights to its own branded product," the presentation said.